JP2020517642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517642A5 JP2020517642A5 JP2019556904A JP2019556904A JP2020517642A5 JP 2020517642 A5 JP2020517642 A5 JP 2020517642A5 JP 2019556904 A JP2019556904 A JP 2019556904A JP 2019556904 A JP2019556904 A JP 2019556904A JP 2020517642 A5 JP2020517642 A5 JP 2020517642A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- disease
- ataxia
- pharmaceutical composition
- mitochondrial dysfunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010003591 Ataxia Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 229940127003 anti-diabetic drug Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000005264 motor neuron disease Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 229940035674 anesthetics Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010050389 Cerebral ataxia Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010015995 Eyelid ptosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims 1
- 208000035172 MERRF Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 108010021592 Pantothenate kinase Proteins 0.000 claims 1
- 102100024122 Pantothenate kinase 1 Human genes 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000006443 lactic acidosis Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000014497 mitochondrial complex deficiency Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000003004 ptosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901457 | 2017-04-21 | ||
| AU2017901457A AU2017901457A0 (en) | 2017-04-21 | Therapeutic compounds and methods | |
| PCT/AU2018/050360 WO2018191789A1 (en) | 2017-04-21 | 2018-04-20 | Therapeutic compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517642A JP2020517642A (ja) | 2020-06-18 |
| JP2020517642A5 true JP2020517642A5 (enExample) | 2021-12-02 |
| JP7266304B2 JP7266304B2 (ja) | 2023-04-28 |
Family
ID=63855520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556904A Active JP7266304B2 (ja) | 2017-04-21 | 2018-04-20 | 治療化合物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10934253B2 (enExample) |
| EP (1) | EP3615502B1 (enExample) |
| JP (1) | JP7266304B2 (enExample) |
| KR (1) | KR102742339B1 (enExample) |
| CN (1) | CN110582480B (enExample) |
| AU (1) | AU2018255492B2 (enExample) |
| CA (1) | CA3056810A1 (enExample) |
| DK (1) | DK3615502T3 (enExample) |
| IL (1) | IL270011B (enExample) |
| MX (1) | MX388592B (enExample) |
| NZ (1) | NZ757526A (enExample) |
| SG (1) | SG11201908568XA (enExample) |
| WO (1) | WO2018191789A1 (enExample) |
| ZA (1) | ZA201906258B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220062205A1 (en) * | 2018-12-17 | 2022-03-03 | Indiana University Research And Technology Corporation | Treatment of gastrointestinal disorders and symptoms thereof |
| CA3156499A1 (en) | 2019-10-04 | 2021-04-08 | Stealth Biotherapeutics Inc. | CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS |
| CN115427027B (zh) * | 2020-03-17 | 2024-12-10 | 滨特劳工公司 | 线粒体功能障碍改善剂 |
| WO2021202986A1 (en) | 2020-04-03 | 2021-10-07 | Stealth Biotherapeutics Corp | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
| US20230212122A1 (en) * | 2020-05-26 | 2023-07-06 | The Regents Of The University Of Michigan | Mitochondrial targeting compounds for the treatment of associated diseases |
| WO2024218322A1 (en) * | 2023-04-21 | 2024-10-24 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Ferroptosis inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5640651A (en) | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
| ZA944568B (en) | 1993-06-25 | 1995-03-20 | Mobius Consultancy Pty Ltd | Therapeutic agent |
| AU3458997A (en) | 1996-07-11 | 1998-02-09 | Takeda Chemical Industries Ltd. | Anti-beta-amyloid protein-induced cytotoxicity composition |
| GB2321455A (en) | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Lipophilic derivatives of biologically active compounds |
| AU5341699A (en) * | 1998-08-06 | 2000-02-28 | University Of Pittsburgh | Antiproliferative naphthoquinones, derivatives, compositions, and uses thereof |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| JP2003226639A (ja) | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用 |
| GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
| JP4769412B2 (ja) * | 2003-09-02 | 2011-09-07 | 積水メディカル株式会社 | 電子メディエーター、電子メディエーター固定化電極およびこれを用いた生物燃料電池 |
| WO2006020959A2 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US20080200441A1 (en) | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators associated pharmaceutical compositions and methods of use |
| DK2220030T3 (en) | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
| EP2262508B1 (en) * | 2008-03-05 | 2018-10-03 | BioElectron Technology Corporation | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| CN104193609B (zh) * | 2008-03-26 | 2017-04-12 | 国家科研中心 | 1，4‑萘醌衍生物及其治疗用途 |
| GB2476643B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants |
| WO2011092284A1 (en) | 2010-01-29 | 2011-08-04 | Euroscreen S.A. | Novel amino acid derivatives and their use as gpr43 receptor modulators |
| WO2011098545A1 (en) | 2010-02-10 | 2011-08-18 | Nattopharma Asa | Novel 2-methyl-1,4-naphthoquinone derivatives and precursors thereof, having vitamin k activity |
| US20130345312A1 (en) * | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| WO2012064396A2 (en) | 2010-08-21 | 2012-05-18 | Georgetown University | Novel ezrin inhibitors and methods of making and using |
| WO2012047628A2 (en) | 2010-09-27 | 2012-04-12 | Emory University | Methods of managing blood sugar levels and compositions related thereto |
| EP3520860A1 (en) | 2011-05-26 | 2019-08-07 | Indiana University Research & Technology Corporation | Quinone compounds for treating ape1 mediated diseases |
| US20140128398A1 (en) | 2011-06-03 | 2014-05-08 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
| WO2013033515A1 (en) | 2011-09-02 | 2013-03-07 | Promega Corporation | Compounds and methods for assaying redox state of metabolically active cells and methods for measuring nad(p)/nad(p)h |
| EP2620141A1 (en) | 2012-01-25 | 2013-07-31 | Santhera Pharmaceuticals (Schweiz) AG | Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014074976A1 (en) * | 2012-11-09 | 2014-05-15 | Musc Foundation For Research Development | Compositions and methods for treating neurological diseases or injury |
| EP2939668A4 (en) | 2012-12-26 | 2016-07-06 | Kitasato Inst | PDK4-HEMMER AND USE THEREOF |
| HK1223369A1 (zh) * | 2013-05-31 | 2017-07-28 | Bioelectron Technology Corporation | 用於治疗氧化应激障碍的羧酸衍生物 |
| JP6703484B2 (ja) | 2014-01-29 | 2020-06-03 | プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ | 細胞による取り込み測定のための、標識用試薬としての、キノンでマスクされたプローブ |
| WO2018194976A1 (en) | 2017-04-17 | 2018-10-25 | Indiana University Research And Technology Corporation | Prevention and reversal of inflammation induced dna damage |
| KR102742508B1 (ko) | 2018-02-08 | 2024-12-12 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 신규한 APE1/Ref-1 저해제를 사용한 눈 질환의 표적화 |
-
2018
- 2018-04-20 DK DK18787365.8T patent/DK3615502T3/da active
- 2018-04-20 MX MX2019012522A patent/MX388592B/es unknown
- 2018-04-20 SG SG11201908568X patent/SG11201908568XA/en unknown
- 2018-04-20 KR KR1020197032321A patent/KR102742339B1/ko active Active
- 2018-04-20 JP JP2019556904A patent/JP7266304B2/ja active Active
- 2018-04-20 US US16/606,842 patent/US10934253B2/en active Active
- 2018-04-20 EP EP18787365.8A patent/EP3615502B1/en active Active
- 2018-04-20 WO PCT/AU2018/050360 patent/WO2018191789A1/en not_active Ceased
- 2018-04-20 CN CN201880026027.4A patent/CN110582480B/zh active Active
- 2018-04-20 AU AU2018255492A patent/AU2018255492B2/en active Active
- 2018-04-20 CA CA3056810A patent/CA3056810A1/en active Pending
- 2018-04-20 NZ NZ757526A patent/NZ757526A/en unknown
-
2019
- 2019-09-20 ZA ZA2019/06258A patent/ZA201906258B/en unknown
- 2019-10-17 IL IL270011A patent/IL270011B/en unknown